Ruud Dobber - AstraZeneca PLC Executive Vice President Europe
| AZNCF Stock | USD 132.42 5.68 4.11% |
President
Mr. Ruud Dobber serves as Executive Vice President, BioPharmaceuticals Business of AstraZeneca PLC. He was appointed Executive VicePresident, BioPharmaceuticals Business in January 2019 and is responsible for product strategy and commercial delivery for CVRM and Respiratory. Prior to this, Ruud held the role of Executive VicePresident, North America and was responsible for driving growth and maximising the contribution of the commercial operations in North America. Ruud joined Zeneca in 1997 and has held various senior commercial and leadership roles including Executive VicePresident, Europe. Ruud was also responsible for the development of our latestage, small molecule antibiotic pipeline as well as its global commercialisation and was Regional VicePresident for European, Middle East and African region, Regional Vice President for the Asia Pacific region and Interim Executive VicePresident, GPPS. Ruud was a member of the Board and Executive Committee of the European Federation of Pharmaceutical Industries and Associations and was previously Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America. Ruud holds a doctorate in immunology from the University of Leiden, Netherlands and began his career as a research scientist in immunology and ageing. since 2019.
| Tenure | 5 years |
| Professional Marks | Ph.D |
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has return on total asset (ROA) of 0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 8 records | PRESIDENT Age | ||
| Miguel Montblanch | Grifols SA ADR | 64 | |
| Yoshitsugu Shitaka | Astellas Pharma | N/A | |
| JeanBaptiste Chatillon | Sanofi ADR | 59 | |
| David Bell | Grifols SA ADR | 70 | |
| Hiroyuki Okuzawa | Daiichi Sankyo | 61 | |
| Alberto Roura | Grifols SA ADR | 65 | |
| Sergio Adell | Grifols SA ADR | 56 | |
| Yoshitsugu Shitaka | Astellas Pharma | N/A | |
Management Performance
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 |
AstraZeneca PLC Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, CFO and Executive Director | ||
| Chris Sheldon, Head Relations | ||
| Pam Cheng, Executive Vice-President of Operations and Information Technology | ||
| MBA DVM, CEO Director | ||
| Gonzalo Vina, Head Relations | ||
| Aradhana MD, CFO Director | ||
| Menelas Pangalos, Executive Vice President - Innovative Medicines | ||
| Katarina Ageborg, Chief Compliance Officer | ||
| Jeffrey Pott, General Counsel | ||
| Ruud Dobber, Executive Vice President Europe |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 241.1 B | |||
| Shares Outstanding | 1.55 B | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 48.84 % | |||
| Price To Earning | 44.18 X | |||
| Price To Book | 6.16 X |
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Pink Sheet
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.